These data suggested more dynamic changes in the CD8+ than CD4+ subsets following ICB-based treatment in AML especially in responders, with the most notable differences occurring in the pretreatment CD8+ GZMK and CD8+ CTL components. The gene discussed is CD8A; the disease is acute myeloid leukemia.